Hims & Hers Acquires At-Home Lab Testing Facility, Expanding Capabilities to Ultimately Include Affordable Whole Body Testing for Subscribers
Hims & Hers Health has announced the acquisition of Sigmund NJ (Trybe Labs), an at-home lab testing facility, to introduce comprehensive lab testing capabilities through its platform. The acquisition, funded through cash on hand, will enable the company to support at-home blood draws and whole body testing using blood lancets.
The new service will allow customers to test hormone levels, cardiac risk, stress markers, cholesterol, liver function, thyroid function, and prostate health. This expansion will facilitate the company's entry into new clinical categories including low testosterone, perimenopausal and menopausal support. The de-identified lab data will also enhance the company's AI developments, including MedMatch.
The integration of lab testing aims to provide more precise clinical decision-making and personalized treatment plans. Hims & Hers plans to roll out at-home testing to customers over the next year.
Hims & Hers Health ha annunciato l'acquisizione di Sigmund NJ (Trybe Labs), una struttura per test di laboratorio a domicilio, per introdurre capacità di test di laboratorio complete attraverso la sua piattaforma. L'acquisizione, finanziata attraverso liquidità disponibile, permetterà all'azienda di supportare prelievi di sangue a domicilio e test dell'intero corpo utilizzando lance per il prelievo del sangue.
Il nuovo servizio consentirà ai clienti di testare i livelli ormonali, il rischio cardiaco, i marcatori di stress, il colesterolo, la funzionalità epatica, la funzionalità tiroidea e la salute della prostata. Questa espansione faciliterà l'ingresso dell'azienda in nuove categorie cliniche, inclusi il testosterone basso e il supporto per la perimenopausa e la menopausa. I dati di laboratorio de-identificati miglioreranno anche gli sviluppi dell'IA dell'azienda, compreso MedMatch.
L'integrazione dei test di laboratorio mira a fornire decisioni cliniche più precise e piani di trattamento personalizzati. Hims & Hers prevede di lanciare i test a domicilio per i clienti nel prossimo anno.
Hims & Hers Health ha anunciado la adquisición de Sigmund NJ (Trybe Labs), una instalación de pruebas de laboratorio en casa, para introducir capacidades de pruebas de laboratorio completas a través de su plataforma. La adquisición, financiada con efectivo disponible, permitirá a la empresa apoyar extracciones de sangre en casa y pruebas de todo el cuerpo utilizando lancetas de sangre.
El nuevo servicio permitirá a los clientes probar los niveles hormonales, el riesgo cardíaco, los marcadores de estrés, el colesterol, la función hepática, la función tiroidea y la salud prostática. Esta expansión facilitará la entrada de la empresa en nuevas categorías clínicas, incluyendo testosterona baja y apoyo perimenopáusico y menopáusico. Los datos de laboratorio desidentificados también mejorarán los desarrollos de IA de la empresa, incluyendo MedMatch.
La integración de pruebas de laboratorio tiene como objetivo proporcionar una toma de decisiones clínicas más precisa y planes de tratamiento personalizados. Hims & Hers planea lanzar pruebas en casa para los clientes en el próximo año.
Hims & Hers Health는 Sigmund NJ (Trybe Labs)의 인수를 발표했습니다. 이는 가정에서 실시할 수 있는 실험실 테스트 시설로, 플랫폼을 통해 종합적인 실험실 테스트 기능을 도입하기 위한 것입니다. 현금으로 자금을 조달한 이번 인수는 회사가 가정에서의 혈액 채취 및 혈액 채취용 란셋을 사용한 전신 테스트를 지원할 수 있게 합니다.
새로운 서비스는 고객이 호르몬 수치, 심장 위험, 스트레스 지표, 콜레스테롤, 간 기능, 갑상선 기능 및 전립선 건강을 테스트할 수 있게 해줍니다. 이번 확장은 저테스토스테론, 생리전증후군 및 폐경기 지원을 포함한 새로운 임상 분야로의 진입을 용이하게 할 것입니다. 비식별화된 실험실 데이터는 또한 회사의 AI 개발, MedMatch를 향상시킬 것입니다.
실험실 테스트의 통합은 보다 정확한 임상 의사결정과 개인화된 치료 계획을 제공하는 것을 목표로 합니다. Hims & Hers는 내년 중 고객을 위한 가정 테스트를 롤아웃할 계획입니다.
Hims & Hers Health a annoncé l'acquisition de Sigmund NJ (Trybe Labs), un laboratoire de tests à domicile, afin d'introduire des capacités complètes de tests de laboratoire via sa plateforme. L'acquisition, financée par des liquidités disponibles, permettra à l'entreprise de soutenir des prélèvements sanguins à domicile et des tests du corps entier à l'aide de lancettes.
Ce nouveau service permettra aux clients de tester les niveaux d'hormones, le risque cardiaque, les marqueurs de stress, le cholestérol, la fonction hépatique, la fonction thyroïdienne et la santé de la prostate. Cette expansion facilitera l'entrée de l'entreprise dans de nouvelles catégories cliniques, notamment le faible taux de testostérone et le soutien à la périménopause et à la ménopause. Les données de laboratoire anonymisées amélioreront également les développements en IA de l'entreprise, y compris MedMatch.
L'intégration des tests de laboratoire vise à fournir des décisions cliniques plus précises et des plans de traitement personnalisés. Hims & Hers prévoit de déployer des tests à domicile pour les clients au cours de l'année prochaine.
Hims & Hers Health hat die Übernahme von Sigmund NJ (Trybe Labs) bekannt gegeben, einer Einrichtung für Labortests zu Hause, um umfassende Labortestmöglichkeiten über ihre Plattform einzuführen. Die Übernahme, die aus verfügbaren Bargeldmitteln finanziert wird, ermöglicht es dem Unternehmen, Blutabnahmen zu Hause und Ganzkörperuntersuchungen mit Blutlanzetten zu unterstützen.
Der neue Service wird es den Kunden ermöglichen, Hormonspiegel, kardiovaskuläre Risiken, Stressmarker, Cholesterin, Leberfunktion, Schilddrüsenfunktion und Prostatagesundheit zu testen. Diese Erweiterung wird den Eintritt des Unternehmens in neue klinische Kategorien, einschließlich niedrigem Testosteron und Unterstützung bei der Perimenopause und Menopause, erleichtern. Die anonymisierten Labordaten werden auch die KI-Entwicklungen des Unternehmens, einschließlich MedMatch, verbessern.
Die Integration von Labortests zielt darauf ab, präzisere klinische Entscheidungen und personalisierte Behandlungspläne bereitzustellen. Hims & Hers plant, im nächsten Jahr Labortests für Kunden einzuführen.
- Strategic acquisition expands service offerings into comprehensive lab testing
- Cash-funded acquisition indicates strong financial position
- Integration with AI developments could enhance personalized healthcare delivery
- Expansion into new clinical categories opens additional revenue streams
- Implementation timeline of one year suggests delayed revenue impact
- Integration costs and operational expenses may affect short-term profitability
Insights
The acquisition of Trybe Labs represents a strategic masterpiece in Hims & Hers' vertical integration strategy, with three key implications for investors:
First, the integration of at-home lab testing significantly expands the company's total addressable market. The U.S. clinical laboratory testing market, valued at over
Second, the acquisition creates a powerful data moat. By collecting proprietary laboratory data and integrating it with their AI platform MedMatch, Hims & Hers is building a competitive advantage that will be difficult for competitors to replicate. This data ecosystem could lead to:
- More accurate treatment recommendations
- Reduced customer acquisition costs through improved retention
- Higher barriers to entry for competitors
- Enhanced predictive capabilities for inventory management
Third, the blood lancet technology addresses a critical friction point in at-home testing by eliminating the need for traditional venipuncture or dried blood spots. This user-friendly approach could accelerate adoption rates and improve testing compliance, particularly among younger demographics who prefer convenient, tech-enabled healthcare solutions.
The cash purchase demonstrates strong financial management, utilizing existing resources without diluting shareholders. While specific financial terms weren't disclosed, the investment in diagnostic capabilities positions Hims & Hers to capture a larger share of the rapidly growing personalized medicine market, estimated to reach
The acquisition will unlock a new level of personalized healthcare and deliver integrated offerings across nutrition, lifestyle, supplements, and medication
The acquisition will unlock a new level of personalized healthcare and deliver integrated offerings across nutrition, lifestyle, supplements, and medication. (Photo: Business Wire)
The company has acquired an at-home lab testing facility, Sigmund NJ LLC marketed as Trybe Labs, which will allow Hims & Hers to support at-home blood draws and more comprehensive whole body testing. The acquisition will broaden the company’s ability to offer a wide range of personalized treatments, supplements and medications and accelerate the expansion into new high-impact clinical categories including low testosterone, perimenopausal and menopausal support.
Using a blood lancet, which eliminates the need for needles or dried blood spot cards, customers will be able to learn more about their hormone levels, cardiac risk, stress markers, cholesterol, liver function, thyroid function, and prostate health. Providers on the platform will then be able to use that information as part of determining a personalized treatment plan most appropriate for their patient. In addition, de-identified lab data will accelerate the company’s AI developments, including MedMatch by Hims & Hers, to get one step closer to delivering an AI-powered healthcare experience that can deliver access to affordable, high-quality care tailored to the individual.
Customers come to the Hims & Hers platform to access treatment across chronic conditions. The company is already able to deliver access to quality and affordable care to more customers by leveraging its clinical expertise, seamless customer experience, and availability of treatment options customized for individuals. With affordable at-home lab testing, customers will be able to access more information about their health and providers can recommend high-quality customized treatments backed by more precise data for each individual patient.
“The healthcare that customers expect and deserve today is on-demand care with treatments designed specifically for them. This next generation of healthcare is what we’re building at Hims & Hers by providing the best information and set of options to each customer that comes to our platform so they can access precisely the care that is best for them,” said Dr. Patrick Carroll, Chief Medical Officer of Hims & Hers. “Access to richer data allows us to deepen the insights that providers can use on our platform to guide their clinical decisions for each individual patient. At-home lab testing is one more exciting step towards elevating the personal, comprehensive care customers in this country should expect.”
Sigmund NJ LLC, marketed as Trybe Labs, is located in
For more information, visit www.hims.com/comprehensive-lab-testing.
About Hims & Hers Health, Inc
Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250219392487/en/
Press Contact
Abby Reisinger
press@forhims.com
Source: Hims & Hers
FAQ
What types of lab tests will HIMS offer through its new acquisition?
When will HIMS launch its at-home lab testing services?
How did HIMS finance the Trybe Labs acquisition?
What new clinical categories will HIMS expand into with this acquisition?
How will the Trybe Labs acquisition enhance HIMS' AI capabilities?
